Summary by Futu AI
On July 2, 2024, iBio's Board approved new forms of award agreements for stock options and restricted stock units under its 2023 Plan. The agreements cover grants to directors, executives, employees, and consultants, with specific provisions for exercise pricing and vesting conditions. Award treatment varies based on termination circumstances, with immediate vesting for death/disability cases and forfeiture for cause terminations.The agreements include special provisions for Sale Events, where non-employee directors receive immediate vesting upon such events. Employees get immediate vesting if terminated without cause or resign with good reason within 12 months after a Sale Event, while officers have similar protections extending one month prior to the Sale Event.Concurrently, the company adopted an updated Code of Business Conduct and Ethics applying to all directors, officers, and employees. The revised code features modernized language and structure, enhanced risk mitigation measures, and better alignment with current operations and work environment.